Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride, the active ingredient in Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It produces reversible pupil dilation and temporary loss of accommodation, facilitating diagnostic eye examinations and accurate refraction measurements. GNH USA supplies Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cyclopentolate Hydrochloride is a mydriatic/cycloplegic agent used in ophthalmic practice. - Diagnostic pupil dilation: provides mydriasis for fundus and retinal examinations. - Cycloplegic refraction: temporarily paralyzes accommodation to allow precise measurement of refractive error. - Anterior uveitis management: used as an adjunct to reduce pain and prevent formation of synechiae.

Cyclopentolate may cause ocular and systemic reactions.

Common Side Effects: - Transient stinging or burning sensation on instillation. - Blurred vision due to loss of accommodation. - Photophobia from prolonged pupil dilation.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma in predisposed eyes. - Systemic anticholinergic toxicity such as dry mouth, tachycardia, or confusion. - Allergic reactions including eyelid edema, rash, or conjunctival hyperemia.

Use of cyclopentolate requires careful assessment of patient risk factors. - Contraindication: known hypersensitivity to cyclopentolate or other anticholinergics. - Caution: patients with narrow‑angle glaucoma should be evaluated before use. - Avoid: routine use in infants and young children unless specifically indicated. - Monitor: elderly patients for systemic anticholinergic effects. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Cyclopentolate can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Systemic anticholinergics (e.g., atropine): additive anticholinergic effects may increase toxicity. - Adrenergic agonists (e.g., phenylephrine): combined use may precipitate a rise in intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may increase ocular irritation when used together. - Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effects. - Oral antihistamines: may enhance systemic anticholinergic symptoms such as dry mouth or dizziness.